RPL23AP37

Across TCGA pan-cancer cohorts, RPL23AP37 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RPL23AP37 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL23AP37 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL23AP37 expression acts as an unfavorable survival marker, although some lineages such as CESC and THCA show a favorable association.

LIHC, CESC, and ACC are the cancer types where RPL23AP37 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.349	0.516	<.001	101	view →
CESC	DFS	Quartile	II,III,IV	0.822	0.299	.002	62	view →
ACC	DFS	Tertile	All	0.209	0.608	.001	47	view →
KICH	DFS	Median	All	0.719	1.000	.006	46	view →
THCA	OS	Median	II,III,IV	1.000	0.548	.002	45	view →
OV	DFS	Median	All	0.342	0.415	.017	38	view →
KIRP	DFS	Quartile	III,IV	0.213	0.828	.004	34	view →
STAD	OS	Quartile	III,IV	0.534	0.735	.010	31	view →
LUAD	OS	Quartile	II,III,IV	0.577	0.895	<.001	28	view →
UCEC	DFS	Quartile	All	0.537	0.682	.011	20	view →
SKCM	OS	Tertile	All	0.826	0.730	.001	18	view →
READ	OS	Median	II,III,IV	1.000	0.807	.005	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

RPL23AP37–LIHC (DFS)

Open the LIHC breakdown →